Alzheimer Disease Familial  >>  cerlapirdine (PF-5212365)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cerlapirdine (PF-5212365) / Pfizer
NCT00479700: Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Subjects

Completed
1
80
US, Europe
SAM-531
Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease
 
07/06
NCT00479297: Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males

Completed
1
72
Japan
SAM-531
Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease
02/07
02/07
NCT00480818: Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly Subjects

Completed
1
80
Europe
SAM-531
Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease
 
07/07
NCT00479349: Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531

Completed
1
32
Japan
SAM-531
Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease
01/08
01/08
NCT00519298: Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects

Completed
1
25
Europe
SAM-531, placebo, Donepezil
Wyeth is now a wholly owned subsidiary of Pfizer
Healthy, Adult
03/08
03/08
NCT00745576: Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered

Completed
1
14
Europe
SAM-531
Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease
12/08
12/08
NCT00726115: Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531

Completed
1
56
Europe
SAM-531, placebo
Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease
02/09
02/09
NCT00906191: Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects

Completed
1
6
Europe
SAM-531
Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease
08/09
08/09
NCT00966966: Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered

Completed
1
17
Europe
SAM-531 and gemfibrozil
Wyeth is now a wholly owned subsidiary of Pfizer, Pfizer
Healthy
12/09
12/09

Download Options